{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:46:36Z","timestamp":1769154396228,"version":"3.49.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":1969,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The ORCHID (Outcomes Related to COVID-19 treated with Hydroxychloroquine among In-patients with symptomatic Disease) trial is a multicenter, blinded, randomized trial of hydroxychloroquine versus placebo for the treatment of adults hospitalized with coronavirus disease (COVID-19). This document provides the rationale and background for the trial and highlights key design features. We discuss five novel challenges to the design and conduct of a large, multicenter, randomized trial during a pandemic, including 1) widespread, off-label use of the study drug before the availability of safety and efficacy data; 2) the need to adapt traditional procedures for documentation of informed consent during an infectious pandemic; 3) developing a flexible and robust Bayesian analysis incorporating significant uncertainty about the disease, outcomes, and treatment; 4) obtaining indistinguishable drug and placebo without delaying enrollment; and 5) rapidly obtaining administrative and regulatory approvals. Our goals in describing how the ORCHID trial progressed from study conception to enrollment of the first patient in 15 days are to inform the development of other high-quality, multicenter trials targeting COVID-19. We describe lessons learned to improve the efficiency of future clinical trials, particularly in the setting of pandemics. The ORCHID trial will provide high-quality, clinically relevant data on the safety and efficacy of hydroxychloroquine for the treatment of COVID-19 among hospitalized adults.<\/jats:p>\n                  <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT04332991).<\/jats:p>","DOI":"10.1513\/annalsats.202005-478sd","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T18:26:19Z","timestamp":1591208779000},"page":"1144-1153","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":26,"title":["Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-290X","authenticated-orcid":false,"given":"Jonathan D.","family":"Casey","sequence":"first","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9915-0591","authenticated-orcid":false,"given":"Nicholas J.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine"},{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-8263","authenticated-orcid":false,"given":"Matthew W.","family":"Semler","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil R.","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Division of Lung Diseases, National Heart, Lung and Blood Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy G.","family":"Brower","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Eppensteiner","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Filbin","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Section of Pulmonary, Critical Care, Allergy and Immunologic Disease, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adit A.","family":"Ginde","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle N.","family":"Gong","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Population Health, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York City, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Harrell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas L.","family":"Hayden","sequence":"additional","affiliation":[{"name":"Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine L.","family":"Hough","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University School of Medicine, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay M.","family":"Leither","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center and University of Utah, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Moss","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathryn F.","family":"Oldmixon","sequence":"additional","affiliation":[{"name":"Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline K.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Michigan, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lora A.","family":"Reineck","sequence":"additional","affiliation":[{"name":"Division of Lung Diseases, National Heart, Lung and Blood Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy J.","family":"Ringwood","sequence":"additional","affiliation":[{"name":"Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryce R. H.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan I.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay S.","family":"Steingrub","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna K.","family":"Torr","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Vanderbilt University Medical Center, Nashville, Tennessee; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Weissman","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Lindsell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd W.","family":"Rice","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Taylor","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-6261","authenticated-orcid":false,"given":"Samuel M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center and University of Utah, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley H.","family":"Self","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2026012203443463500_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.3072","article-title":"COVID-19-New insights on a rapidly changing epidemic","volume-title":"JAMA","author":"Del Rio"},{"key":"2026012203443463500_bib2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMe2002387","article-title":"Covid-19 - navigating the uncharted","volume":"382","author":"Fauci","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012203443463500_bib3","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012203443463500_bib4","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012203443463500_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"2026012203443463500_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume-title":"Clin Infect Dis","author":"Yao"},{"key":"2026012203443463500_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2026012203443463500_bib8","doi-asserted-by":"crossref","first-page":"105982","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies","volume":"55","author":"Zhao","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2026012203443463500_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026012203443463500_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume-title":"JAMA","author":"Sanders"},{"key":"2026012203443463500_bib11","article-title":"Hydroxychloroquine","author":"DrugBank"},{"key":"2026012203443463500_bib12","doi-asserted-by":"crossref","first-page":"e00293","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"2026012203443463500_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"2026012203443463500_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"2026012203443463500_bib15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2026012203443463500_bib16","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2026012203443463500_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"2026012203443463500_bib18","article-title":"Massachusetts General Hospital COVID-19 Treatment Guidance","author":"Massachusetts General Hospital.","year":"2020"},{"key":"2026012203443463500_bib19","article-title":"Brigham and Women\u2019s Hospital COVID-19 critical care clinical guidelines","author":"Brigham and Women\u2019s Hospital","year":"2020"},{"key":"2026012203443463500_bib20","article-title":"YNHHS initial treatment algorithm for hospitalized ADULTS with non-severe COVID-19","author":"Yale School of Medicine.","year":"2020"},{"key":"2026012203443463500_bib21","article-title":"COVID-19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International Task Force","author":"Wilson","year":"2020"},{"key":"2026012203443463500_bib22","article-title":"Emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 coronavirus disease","author":"Food and Drug Administration (FDA)"},{"key":"2026012203443463500_bib23","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume-title":"Int J Antimicrob Agents","author":"Gautret"},{"key":"2026012203443463500_bib24","doi-asserted-by":"crossref","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial [preprint]","author":"Chen","DOI":"10.1101\/2020.03.22.20040758"},{"key":"2026012203443463500_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med Mal Infect"},{"key":"2026012203443463500_bib26","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"Chen","year":"2020","journal-title":"J Zhejiang Univ (Med Sci)"},{"key":"2026012203443463500_bib27","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with covid-19","volume-title":"N Engl J Med","author":"Geleris"},{"key":"2026012203443463500_bib28","article-title":"Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment","volume-title":"Circulation","author":"Roden Dan"},{"key":"2026012203443463500_bib29","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026012203443463500_bib30","author":"National Institutes of Health"},{"key":"2026012203443463500_bib31","article-title":"Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj","year":"2020"},{"key":"2026012203443463500_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026012203443463500_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1513\/AnnalsATS.201608-629OT","article-title":"Design and rationale of the reevaluation of systemic early neuromuscular blockade trial for acute respiratory distress syndrome","volume":"14","author":"Huang","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203443463500_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.annemergmed.2018.03.039","article-title":"Liberal versus restrictive intravenous fluid therapy for early septic shock: rationale for a randomized trial","volume":"72","author":"Self","year":"2018","journal-title":"Ann Emerg Med"},{"key":"2026012203443463500_bib35","article-title":"FDA guidance on conduct of clinical trials of medical products during COVID-19 public health emergency","author":"U.S. Food and Drug Administration.","year":"2020"},{"key":"2026012203443463500_bib36","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1128\/AAC.00339-08","article-title":"Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax","volume":"53","author":"Lim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203443463500_bib37","article-title":"Coronavirus disease (COVID-2019) R&D: COVID-19 therapeutic trial synopsis","author":"World Health Organization"},{"key":"2026012203443463500_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol: a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"2026012203443463500_bib39","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2026012203443463500_bib40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00134-020-05934-6","article-title":"Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop","volume":"46","author":"Harhay","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026012203443463500_bib41","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1164\/rccm.202004-1163LE","article-title":"Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study","volume":"201","author":"Ziehr","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203443463500_bib42","article-title":"Remdesivir for the treatment of covid-19 - preliminary report","volume-title":"N Engl J Med","author":"Beigel"},{"key":"2026012203443463500_bib43","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1056\/NEJMoa1911124","article-title":"Early high-dose Vitamin D 3 for critically ill, Vitamin D-deficient patients","volume":"381","author":"Ginde","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203443463500_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2106\/JBJS.K.01412","article-title":"The dangers of stopping a trial too early","volume":"94","author":"Briel","year":"2012","journal-title":"J Bone Joint Surg Am"},{"key":"2026012203443463500_bib45","doi-asserted-by":"crossref","first-page":"209S","DOI":"10.1016\/0197-2456(89)90059-7","article-title":"Practical problems in interim analyses, with particular regard to estimation","volume":"10","author":"Pocock","year":"1989","journal-title":"Control Clin Trials"},{"key":"2026012203443463500_bib46","article-title":"In defense of evidence-based medicine for the treatment of COVID-19 ARDS","volume-title":"Ann Am Thorac Soc","author":"Rice"},{"key":"2026012203443463500_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6434","article-title":"Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis","volume-title":"JAMA","author":"Goodman"},{"key":"2026012203443463500_bib48","doi-asserted-by":"crossref","DOI":"10.1165\/rcmb.2020-0151LE","article-title":"A call for rational intensive care in the era of COVID-19","volume-title":"Am J Respir Cell Mol Biol","author":"Singer"},{"key":"2026012203443463500_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4742","article-title":"Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics","volume-title":"JAMA","author":"Kalil"},{"key":"2026012203443463500_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4984","article-title":"Optimizing the trade-off between learning and doing in a pandemic","volume-title":"JAMA","author":"Angus"},{"key":"2026012203443463500_bib51","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.202004-1153ED","article-title":"COVID-19: first do no harm","volume":"201","author":"Waterer","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203443463500_bib52","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1097\/CCM.0000000000004363","article-title":"Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)","volume":"48","author":"Alhazzani","year":"2020","journal-title":"Crit Care Med"},{"key":"2026012203443463500_bib53","article-title":"Research C for DE and use of electronic informed consent in clinical investigations: questions and answers","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"2026012203443463500_bib54","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/cid\/cix1061","article-title":"Regulatory and operational complexities of conducting a clinical treatment trial during an ebola virus disease epidemic","volume":"66","author":"Rojek","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026012203443463500_bib55","doi-asserted-by":"crossref","first-page":"20160294","DOI":"10.1098\/rstb.2016.0294","article-title":"Offering patients more: how the West Africa Ebola outbreak can shape innovation in therapeutic research for emerging and epidemic infections","volume":"372","author":"Rojek","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/17\/9\/1144\/66349203\/annalsats_17_9_1144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/17\/9\/1144\/66349203\/annalsats_17_9_1144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:49:51Z","timestamp":1769071791000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/17\/9\/1144\/8418735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202005-478sd","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"2020-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}